NovaBay Pharmaceuticals Special Meeting of Stockholders Set for December 18, 2024
NovaBay Pharmaceuticals, Inc. recently announced that their Special Meeting of Stockholders, which took place on November 22, 2024, has been adjourned until December 18, 2024. This extension was granted to allow more time for stockholders to vote on Proposal One and Proposal Two, which received notable support but fell short of the required 50% threshold of favorable votes from all outstanding shares of common stock.
Proposal One involves the sale of Avenova, which represents a significant portion of the company’s assets, while Proposal Two pertains to the liquidation and dissolution of the company. As of the initial meeting, approximately 89.0% of the votes cast were in favor of Proposal One, and 88.5% were in favor of Proposal Two. Both proposals are believed to be in the best interests of NovaBay and its stockholders.
The adjourned meeting will be conducted virtually, and stockholders can participate by visiting http://www.virtualshareholdermeeting.com/NBY2024SM and entering the 16-digit control number from their proxy card. If you are a stockholder as of the record date of October 15, 2024, and have not yet voted or are unsure if your shares have been voted, NovaBay encourages you to reach out to your broker or bank to ensure your vote is counted.
The Company encourages all stockholders to consider voting in favor of Proposal One and Proposal Two. Your voice matters, and your participation is essential to the decision-making process. Let’s work together to shape the future of NovaBay Pharmaceuticals, Inc.
